沃森生物(300142.SZ)將以1.5億元參與設立投資基金 以投資生物醫藥產業鏈相關的優質資產
格隆匯8月24日丨沃森生物(300142.SZ)公佈,為促進公司產業鏈進一步拓展,2019年8月22日,公司第四屆董事會第二次會議和第四屆監事會第二次會議審議通過了《關於簽署珠海橫琴沃森投資基金合夥企業(有限合夥)認購協議的議案》。
公司將以自有資金出資1.5億元與合作方共同投資設立珠海橫琴沃森投資基金合夥企業(有限合夥)(名稱以工商註冊為準,“基金”),並簽署《珠海橫琴沃森投資基金合夥企業(有限合夥)認購協議》,基金規模為6.07億元。該基金將用於投資生物醫藥產業鏈相關的優質資產,並進一步擴展公司旗下現有各子公司的研發、生產規模,增強各子公司的資金投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.